All Episodes
COR2ED - Oncology Medical Conversation — 92 episodes
Pre-analytical phase challenges and biomarker testing in HER2+ metastatic breast cancer
Metastatic breast cancer: Understanding HER2-low and HER2-ultralow classification
Understanding EP-NEC: Through Diagnosis, Treatment, and Support
Exploring the role of targeted radiopharmaceutical treatment in NETs
Tackling mPDAC: chemotherapy strategies that matter
Understanding Rare NSCLC Mutations: Insights, access and support
The HER2 diagnostic and treatment landscape in NSCLC
The HER2 Diagnostic and Treatment Landscape in NSCLC
ER+ metastatic breast cancer: Key insights on elacestrant from the latest EMERALD subgroup analyses
Best practices in molecular testing and targeted therapy for HR+/HER2- metastatic breast cancer
Advanced or recurrent endometrial cancer: Molecular classification and treatment decisions
Intermediate HCC – The evolving role of IO
Intermediate HCC – treatment options and strategies
HCC podcast series part 2: 2nd line treatment in advanced HCC and when to switch
Testing to treatment of BRAF-mutant metastatic NSCLC
HCC podcast series part 1: The use of IO in unresectable HCC
BRAF-mutated CRC: testing to treatment
Neuroendocrine tumours (NETs) – Shared decision-making. Part 2: Individualising treatment decisions
Neuroendocrine tumours (NETs) – Shared decision-making. Part 1: Patient journey
Regional differences in NET: Treatment and future developments
Regional differences in NET: Epidemiology, diagnosis, and referral strategies
Understanding the needs of different patient populations in colorectal cancer
Interpreting real-world evidence in later-line mCRC
Cáncer de ovario: dificultades en la fase preanalítica y pruebas de biomarcadores
Câncer de ovário: Desafios da fase pré-analítica e teste de biomarcadores
Cáncer de próstata: dificultades en la fase preanalítica y pruebas de biomarcadores
Câncer de Próstata: Desafios da Fase Pré-Analítica e Teste de Biomarcadores
Cáncer de pulmón: dificultades en la fase preanalítica y pruebas de biomarcadores
Câncer de pulmão: Desafios da fase pré-analítica e teste de biomarcadores
mCRC: Optimising patient outcomes with late-line treatment
Perseverance pays off – Looking beyond the obvious mutations in NSCLC
Ovarian cancer: Pre-analytical phase challenges and biomarker testing
Lung cancer: Pre-analytical phase challenges and biomarker testing
Treatment optimization in mCRC: third-line and beyond
Precision oncology: An overview of tumour agnostic therapies
Prostate Cancer: Pre-Analytical Phase Challenges and Biomarker Testing
Severe PHH. Part 2 - Learnings from clinical practice
Managing thrombosis: Part 2 - Cancer and thrombosis
Advanced HCC: 2nd line treatment and the right time to switch
Breast cancer: Oral SERDs in ER+ BC. Part 3 - Rare cases & treatment challenges
Precision oncology: An introduction to molecular testing
Breast cancer: Oral SERDs in ER+ BC. Part 2 - Treatment selection and beyond
Gastric and GEJ cancers: Clinical case discussions. Part 2 - metastatic disease
Gastric and GEJ cancers: Clinical case discussions. Part 1 - non-metastatic disease
Breast cancer: Oral SERDs in ER+ BC. Part 1 - Efficacy, safety and the treatment landscape
Prostate cancer: Treatment intensification in mCSPC - The nurse perspective
Colorectal cancer: Treatment sequencing in advanced mCRC
Prostate cancer: Which mCSPC patients benefit from early treatment intensification? Case-based discussion
Prostate cancer: PARP inhibitors. Part 3 - Efficacy and safety of combination therapy
Advanced HCC: Patients not eligible for IO - What are the treatment options?
Prostate cancer: PARP inhibitors. Part 2 - Combination therapy; US and EU perspectives
Prostate cancer: PARP inhibitors. Part 1 - PARPi monotherapy; US and EU perspectives
Endometrial carcinoma: Systemic therapies. Part 2 - The nurses' perspective
Endometrial carcinoma: Systemic therapies. Part 1 - The physicians' perspective
Lower GI cancer: Highlights from ASCO GI 2023 - Part 2
Upper GI cancer Highlights from ASCO GI 2023 - Part 1
Sarcoma: Updates from CTOS 2022
Advanced RCC: Clinical implementation of targeted therapies and immunotherapies
Neuroendocrine tumours: The role of SSA at progression - To continue or not?
HCC: Updates from ILCA and ESMO 2022
Upper GI cancer: Update from ESMO 2022 - Part 2
Lower GI cancer: Update from ESMO 2022 - Part 1
Colorectal cancer: Flexible dosing of oral treatments in mCRC
Sarcoma: Updated bone sarcoma guidelines - Clinical implications
HCC: The role of immunotherapy beyond advanced HCC
Prostate cancer: Highlights from ASCO GU, ASCO and EAUN 2022
Prostate cancer: Shared decision-making in nmCRPC
Prostate cancer: Timing of ARSI and taxanes in mCSPC
GI cancer: Management of skin toxicity from multikinase inhibitors
Multiple Myeloma: Choosing the best treatment regimen in patients with high-risk cytogenetics - Part 3
Prostate cancer: Highlights from ASCO GU 2022
HCC: Key topics discussed at ASCO GI & EASL 2022
Prostate cancer: PARP inhibitors in prostate cancer
Cáncer de próstata: Inhibidores de PARP - lo que las enfermeras necesitan saber
Prostate cancer: PARP inhibitors in prostate cancer - What nurses need to know
Prostate cancer: Genetic testing and PARP inhibitors in prostate cancer
Precision oncology: Detection and treatment of TRK fusion-positive lung cancers
HCC: VEGFR-TKIs alone or in combination with immune checkpoint inhibitors
RCC: Treating advanced RCC - The role of VEGFR-TKIs alone or in combination therapy
Colorectal and gastric cancer: Current and future therapeutic approaches. Part 3 - Future developments
Colorectal and gastric cancer: Current and future therapeutic approaches. Part 2 - Immunotherapy
Colorectal and gastric cancer: Current and future therapeutic approaches. Part 1 - Targeted therapy
Multiple Myeloma: Choosing the best treatment regimen in patients with relapsed/refractory MM - Part 2
HCC: VEGFR-TKI monotherapy for unresectable or advanced HCC in 1st line setting
Multiple Myeloma: Choosing the best treatment regimen in newly diagnosed patients - Part 1
HCC: Highlights from ILCA and ESMO 2021
Precision oncology: Diagnosis and treatment of TRK fusion-positive GI cancers
VEGFR-TKIs: Nurse management of adverse events
Thyroid cancer: Optimising VEGFR-TKIs (MKIs) in differentiated thyroid cancer
HCC: Highlights from ASCO and WCGIC 2021
Prostate cancer: Radiopharmaceuticals. Part 2 - PSMA theranostics
Prostate cancer: Radiopharmaceuticals. Part 1 - Radium-223